ZEISS announces partnership with the European Association of Neurosurgical Societies

In cooperation with the renowned medical society, ZEISS promotes further training of specialists and advances scientific progress in the field of neurosurgery.

Jena, Germany | 27 October 2022 | Carl Zeiss Meditec AG

ZEISS Medical Technology announces the strategic partnership with the European Association of Neurosurgical Societies (EANS). With this partnership, the company aims to support the training and further education of neurosurgical specialists, to promote sharing of experiences between users and medical technology manufacturers and to advance scientific progress in the field of neurosurgery.

"We are pleased that a renowned scientific society like the EANS is entering into a partnership with ZEISS, and it is an appreciation of our innovation leadership. Collaboration with surgeons, has enabled ZEISS to shape neurosurgery" says Magnus Reibenspiess, Head of the Microsurgery Strategic Business Unit at ZEISS Medical Technology. "In the field of learning in particular, close cooperation with the members of EANS will make it possible to integrate and establish new solutions in neurosurgical workflows."

Promote training and further education of neurosurgical specialists

Close networking in the field of learning enables knowledge and information sharing between medical specialists and medical technology manufacturers. Therefore, the training and further education of neurosurgeons is a focal point of the partnership between EANS and ZEISS.

ZEISS provides various visualization systems and solutions for the EANS training programs and speciality courses, while supporting the development of teaching offers for new and existing technologies. As a partner, ZEISS is also committed to virtual formats such as the EANS Academy.

Drive innovation and support neurosurgical research

Cooperation with scientists and users has always been part of the ZEISS corporate culture. The company sees the partnership with EANS as an opportunity to address current clinical challenges in neurosurgery. Together with users, ZEISS not only aims to develop innovations and solutions for neurosurgery but also to integrate existing technologies into clinical workflows in the best possible way.

In addition, as a sponsor of the EANS Research Fund, ZEISS will contribute significantly to scientific progress in the field of neurosurgery and promote the formation and propagation of knowledge within the neurosurgical community.

The company announced the partnership at the EANS annual Congress in Belgrade (Serbia), where ZEISS presented its neurosurgery solutions from 16 October to 20 October 2022.

For information on ZEISS neurosurgery solutions, please visit: https://www.zeiss.com/meditec/en/home.html

Press Contact

Sebastian Frericks
Director Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220-116
investors .meditec @zeiss .com

Petra Rettenmaier
Head of Marketing Communications Visualization
Carl Zeiss Meditec AG
Telefon: +49 3641 220 331
press .med @zeiss .com

Brief Profile

Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world’s leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With approximately 3,531 employees worldwide, the Group generated revenue of €1,646.8m in fiscal year 2020/21 (to 30 September).

The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG’s shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.

For further information visit: www.zeiss.com/med

Press Contact

Sebastian Frericks
Director Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220-116
investors .meditec @zeiss .com

Petra Rettenmaier
Head of Marketing Communications Visualization
Carl Zeiss Meditec AG
Telefon: +49 3641 220 331
press .med @zeiss .com

Share
Further Articles

ZEISS Receives FDA Clearance for MTLawton

ZEISS Receives FDA Clearance for MTLawton – A New Generation of Bipolar Forceps for Electrosurgery

10 Oct 2022

Change to the Management Board of Carl Zeiss Meditec AG

Management Board member Jan Willem de Cler to leave the Company at his own request and on good terms.

8 Sep 2022

ZEISS Integrated Workflow Solutions are Creating the Digital Transformation in Healthcare

The fully connected environment, digital technologies and artificial intelligence tools enable optimization of patien...

30 Aug 2022